JPRN-jRCT2080223014未知2 期
A phase 2, randomized, double-blind, dose finding study of DS-8500a in Japanese patients with type 2 diabetes mellitus
DAIICHISANKYO Co.,Ltd.0 个研究点目标入组 335 人开始时间: 2015年11月13日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 335
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Main Inclusion Criteria;
- •1)Patients aged >= 20 years
- •2)Japanese patients with type 2 diabetes mellitus
- •3)Patients who have >= 7.0% and < 10.0% HbA1c
排除标准
- •Main Exclusion Criteria;
- •-Patients with type 1 diabetes mellitus or with a history of diabetic coma, precoma, or ketoacidosis
- •-Patients receiving or requiring treatment with insulin
- •-Patients with a body mass index (BMI) of < 18.5 kg/m2 or >= 35.0 kg/m2
- •-Patients with clinically evident renal impairment (estimated glomerular filtration rate [eGFR] of < 45 mL/min per 1.73 m2) or clinically significant renal disease
- •-Patients with fasting plasma glucose >= 240 mg/d
研究者
相似试验
进行中（未招募）
1 期
A randomized phase 2 study to determine the dose, and assessthe efficacy, safety, and tolerability of Gemcabene in Patients withHypercholesterolemia.HypercholesterolaemiaMedDRA version: 19.0Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2015-005756-10-DKGemphire Therapeutics Inc.212
已完成
2 期
A phase II, double blind, randomised, dose ranging, safety and efficacy trial of rapid intravenous infusion of Zoledronate versus Aredia in breast cancer patients with osteolytic metastasesCancerBreast cancerISRCTN29188871Cancer Research UK (CRUK) (UK)
招募中
2 期
AVX754 (nucleoside reverse transcriptase inhibitor) to treat drug resistant HIVHIV InfectionsACTRN12605000742673Avexa Ltd60
进行中（未招募）
1 期
A Phase 2a, dose-finding, randomized, double-blinded, placebo-controlled study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Efavirenz in Patients with Early Alzheimer’s DiseaseAlzheimer's DiseaseCTIS2023-509613-37-01Amsterdam UMC40
进行中（未招募）
1 期
A Phase II, double blind, placebo controlled, dose-ranging study in patients with post herpetic neuralgia (PHN) to evaluate the efficacy, safety, tolerability and pharmacokinetics of four doses of TAK-583, compared with placebo.Postherpetic neuralgiaMedDRA version: 7.1 Level: LLT Classification code 10019979EUCTR2005-005863-26-GBTakeda Global Research & Development Centre (Europe) Ltd